Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1671
This examiner grants 29% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18017955 | ADENOVIRUS VECTORS AND METHODS FOR USING ADENOVIRUS VECTORS | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18021262 | Pharmaceutical Composition Comprising Hepatitis B Virus-Derived Polypeptide for Prevention or Treatment of Cancer | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17633353 | COMBINED USE OF ARTIFICIAL ADJUVANT VECTOR CELLS AND AN IMMUNOSTIMULANT | Non-Final OA | RIKEN |
| 18255154 | NOVEL COMPOSITIONS WITH TISSUE-SPECIFIC TARGETING MOTIFS AND COMPOSITIONS CONTAINING SAME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18042955 | HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN | Final Rejection | The University of Tokyo |
| 17995050 | METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19 | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17821411 | COMPOSITIONS AND METHODS FOR DETECTING SARS-CoV-2 | Final Rejection | The University of Hong Kong |
| 18080639 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | Non-Final OA | Janssen Biotech, Inc. |
| 18249999 | SARS-COV-2 ANTIBODIES AND USES THEREOF | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 17796561 | TAT PEPTIDE BINDING PROTEINS AND USES THEREOF | Final Rejection | The United States of America, as Represented by the Secretary, Dept. of Health and Human Services |
| 17623792 | ANTIBODY TO LEPTIN RECEPTOR | Final Rejection | SHANGHAITECH UNIVERSITY |
| 17925474 | COMPOSITIONS AND METHODS FOR TREATING AND DETECTING CORONAVIRUS INFECTION | Non-Final OA | HOWARD UNIVERSITY |
| 17635534 | CELL THERAPY METHODS | Final Rejection | Universität Basel |
| 18554972 | RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | Jiangsu Kanion Pharmaceutical Co., Ltd. |
| 17914868 | RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD THEREFOR, RECOMBINANT PLASMID, AND USE THEREOF | Final Rejection | JIANGSU KANION PHARMACEUTICAL CO., LTD. |
| 18283363 | ATTENUATED REOVIRUS-BASED VACCINE COMPOSITION AND USE THEREOF | Non-Final OA | VIROCURE, INC. |
| 18274551 | Detecting SARS-CoV-2 and Other Infective Agents | Non-Final OA | Incite Health, Inc. |
| 18255748 | A PROCESS AND A KIT FOR DETECTION OF CORONAVIRUS AND OTHER RESPIRATORY VIRUSES | Non-Final OA | Council of Scientific and Industrial Research |
| 18254373 | IMMUNITY AND PROTECTION OF SARS-COV-2 DNA AND PROTEIN VACCINE | Non-Final OA | Shan LU |
| 17927804 | SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES | Non-Final OA | Universite Paris Est Creteil Val de Marne |
| 18245248 | Method for Preparing Stem Cells Having Improved Engraftment Capability | Final Rejection | Generoath Co., Ltd. |
| 18042448 | SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2 | Non-Final OA | Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
| 18018618 | ANTIVIRAL COMPOSITION AGAINST CORONAVIRUS | Final Rejection | NOVELGEN CO., LTD. |
| 17891404 | PRETREATMENT METHOD, PRETREATMENT SOLUTION, AND KIT FOR DETECTING NUCLEIC ACID OF VIRUS, AND USE THEREOF | Non-Final OA | SANSURE BIOTECH INC. |
| 17802758 | HIGH DOSE FLU VACCINE IN PEDIATRIC SUBJECTS | Final Rejection | Sanofi Pasteur Inc. |
| 17766724 | COMBINATION THERAPY FOR CANCERS WITH KRAS MUTATION | Non-Final OA | COTHERA BIOSCIENCE, INC. |
| 17561089 | ANTI-ALPP CAR-T CELL THERAPY | Non-Final OA | TCRCURE BIOPHARMA CORP. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy